FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas.

Sarraf Yazdy M, Kasamon YL, Gu W, Rodriguez LR, Jin S, Bhatnagar V, Richardson NC, Theoret MR, Pazdur R, Gormley NJ

DOI: 10.1158/1078-0432.ccr-24-1729
Published: 2024 Dec 16
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-24-1729,
  title = {FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas.},
  author = {Sarraf Yazdy M and Kasamon YL and Gu W and Rodriguez LR and Jin S and Bhatnagar V and Richardson NC and Theoret MR and Pazdur R and Gormley NJ},
  year = {2024},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-24-1729},
  url = {https://doi.org/10.1158/1078-0432.ccr-24-1729}
}

RIS

TY  - JOUR
TI  - FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas.
AU  - Sarraf Yazdy M
AU  - Kasamon YL
AU  - Gu W
AU  - Rodriguez LR
AU  - Jin S
AU  - Bhatnagar V
AU  - Richardson NC
AU  - Theoret MR
AU  - Pazdur R
AU  - Gormley NJ
PY  - 2024
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-24-1729
UR  - https://doi.org/10.1158/1078-0432.ccr-24-1729
ER  -

APA

M, S. Y., YL, K., W, G., LR, R., S, J., V, B., NC, R., MR, T., R, P., & NJ, G. (2024). FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-24-1729

Source records

pubmed · retrieved 2026-09-27T16:00:51.116Z